AngioDynamics(NASDAQ) ANGO

AngioDynamics NASDAQ:ANGO makes tools that help doctors treat cancer and heart disease. Their products allow medical professionals to perform surgeries with fewer cuts. These instruments help patients recover faster from vascular and oncology procedures.

High-Tech Tools for Modern Surgery

• Med Tech Segment: Specialized tools including the NanoKnife system for tissue removal and Auryon laser for vascular disease; generated $39.9 million in net sales in the three months ended Aug. 31, 2026.
• Med Device Segment: Everyday surgical tools such as catheters, ports, and microwave systems; generated $41.0 million in net sales in the three months ended Aug. 31, 2026.
• Thrombus Management: Systems designed to help doctors remove blood clots from veins and arteries.
• Vascular Access: Devices such as catheters and ports used to deliver medicines like chemotherapy into the bloodstream.

Narrowing the Focus

• Divested the PICCs, Midline, dialysis, and BioSentry businesses to focus on higher-growth medical technology categories.
• Transitioned certain product lines to third-party manufacturing to improve overall operational costs.
• Restructured the manufacturing footprint through a plan announced on Jan. 5, 2024, to optimize production.
• Expanded the clinical use of the Auryon and NanoKnife platforms through research and development.

Reaching Doctors Worldwide

AngioDynamics sells products through a direct sales force in the United States and uses international distributors to reach global healthcare providers. The company focuses on minimally invasive, image-guided procedures that aim to improve patient quality of life.

A Look at the Books

• Net sales rose 6.9% to $80.9 million in the three months ended Aug. 31, 2026.
• Total company gross margin reached 59.4% in the three months ended Aug. 31, 2026, up 410 basis points year over year.
• Net loss was $7.1 million in the three months ended Aug. 31, 2026, a $3.8 million improvement year over year.
• Cash and cash equivalents totaled $34.0 million as of Aug. 31, 2026, with zero outstanding debt.
• Med Tech net sales grew 13.2% to $39.9 million in the three months ended Aug. 31, 2026.

Bottom Line

AngioDynamics is shifting its focus toward high-tech oncology and vascular solutions while streamlining its manufacturing operations. This transition from basic medical supplies to advanced technology aims to improve profitability and long-term market position.